Status:
COMPLETED
MCT8 Deficiency Caregiver Study
Lead Sponsor:
Rare Thyroid Therapeutics International AB
Collaborating Sponsors:
Vitaccess Ltd
Conditions:
Monocarboxylate Transporter 8 (MCT8) Deficiency
Allan-Herndon-Dudley Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Caregivers face many responsibilities outside of their role as a friend or parent, which can lead to emotional, financial, social, and professional challenges. To better understand the impact of MCT8 ...
Detailed Description
Understanding the impact of MCT8 deficiency on caregivers and patients is key to facilitating evidence-based policy interventions and identifying better treatments and treatment practices that take fu...
Eligibility Criteria
Inclusion
- 18 years or older
- Resident in the UK, US, Canada (except Newfoundland \& Labrador and Alberta), France, Netherlands, Spain, Australia, Italy, and Germany
- Main caregiver to a person diagnosed with MCT8 deficiency
Exclusion
- Paid caregivers to a person diagnosed with MCT8 deficiency
Key Trial Info
Start Date :
August 23 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 12 2024
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT06060197
Start Date
August 23 2022
End Date
April 12 2024
Last Update
April 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vitaccess Ltd
Oxford, Oxfordshire, United Kingdom, OX4 4GA